Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.

Omid HamidKarl D LewisAmy WeiseMeredith A McKean Kyriakos P PapadopoulosJohn CrownTae Min Kim Dae Ho Lee Sajeve S Thomas Janice MehnertJohn KaczmarNehal J Lakhani Kevin B Kim Mark Ross Middleton Guilherme Rabinowits Alexander I SpiraMelinda YushakInderjit MehmiFang FangShuquan ChenJayakumar ManiVladimir JankovicFang WangNathalie FiaschiLaura BrennanAnne J PaccalySheila MasindeMark SalvatiMatthew G FuryGlenn S KroogIsrael LowyGiuseppe Gullo

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

The current results show a promising benefit-risk profile of fianlimab/cemiplimab combination for patients with advanced melanoma, including those with previous anti-PD-1 therapy in the adjuvant, but not advanced, setting.

Keyphrases

monoclonal antibody
endothelial cells
early stage
skin cancer
genome wide
induced pluripotent stem cells
peripheral blood
gene expression
basal cell carcinoma
dna methylation
bone marrow
smoking cessation